Get started

When Antibiotics Make You Sicker: The Hidden Danger of Misdiagnosed Fungal Infections

by , | Mar 31, 2026 | Mold and Health

Elizabeth Sager was 24 years old when she walked into an emergency room with a mysterious infection. Doctors sent her home with antibiotics.

Within a week, she was airlifted to a hospital in critical condition.

Physicians found a deadly fungus spreading through her bloodstream, liver, and bone marrow.

The antibiotics prescribed to save her had actually almost killed her.

Her case is not an anomaly.

It is a pattern — a dangerous, widespread, and largely invisible problem playing out in hospitals and clinics around the world every day.

Fungal infections are rising.

Diagnostic tools are lagging.

And antibiotics, the most prescribed medications in modern medicine, are quietly making millions of people more vulnerable to deadly fungal disease.

This article breaks down how that happens, why it keeps happening, and what every patient and provider needs to know.

How Antibiotics Open the Door to Fungi

To understand the problem, you have to understand how your body keeps fungi in check.

Your gut, skin, lungs, and mucous membranes host a carefully balanced community of bacteria and fungi.

These microbial communities compete with each other for space and resources. When bacteria are healthy and plentiful, they crowd out opportunistic fungi — especially Candida albicans, the yeast responsible for most fungal infections in humans.

Antibiotics disrupt that balance.

They kill bacteria — including the beneficial ones — without touching fungi at all.

This creates an open ecological window for fungal overgrowth.

A 2022 study published in PubMed provided the first direct clinical evidence confirming this process in healthy humans.

Researchers found that antibiotic treatment increases the proportion of fungi in the gut and disturbs the fungal microbiome composition, particularly Candida albicans, in a subject-dependent manner.

A 2024 study expanded on this, showing that antibiotic-induced gut dysbiosis promotes Candida growth — and that in hospitalized patients with lung disease, fungal overgrowth correlated directly with longer hospital stays.

The mechanism goes deeper than just microbiome balance.

A landmark 2022 study published in Cell Host & Microbe found that long-term antibiotic exposure impaired the immune system’s ability to fight fungal infections by reducing critical immune signaling molecules — specifically cytokines called IL-17A and GM-CSF — in the gut.

In plain terms: antibiotics don’t just remove the bacterial competition. They actually cripple the immune cells that are supposed to stop fungi from spreading.

According to the research team writing in The Conversation, “Antibiotics can cause immune system defects that increase the risk of dangerous fungal infections”.

In their mouse model, antibiotic-treated subjects developed fungal infections in the intestines and then experienced bacterial escape into the bloodstream — resulting in a compounded infection that was far more life-threatening than either infection alone.

A 2019 study in Scientific Reports added another layer, showing that antibiotics reduce short-chain fatty acids (SCFAs) in the gut, which are normally produced by bacteria and help suppress Candida colonization. Fewer SCFAs mean more space for Candida to grow and eventually invade.

The bottom line: every round of antibiotics carries a real, measurable risk of triggering a fungal infection — especially in patients who are elderly, immunocompromised, hospitalized, or already sick.

The Misdiagnosis Crisis: When Doctors Treat the Wrong Enemy

The second — and arguably more dangerous — part of this story is what happens when a fungal infection is already present but is mistaken for a bacterial one.

Fungal and bacterial infections can look almost identical on the surface. Both cause fever, fatigue, cough, swelling, and respiratory distress. In hospital settings, this overlap is especially deadly.

Doctors under time pressure rely on clinical signs rather than waiting for culture results, and clinical signs can deceive them.

Researchers from the Global Action Fund for Fungal Infections (GAFFI), writing in Emerging Infectious Diseases, identified four common clinical scenarios where this misdiagnosis regularly occurs:

Fungal sepsis misidentified as bacterial sepsis in ICU settings, leading to inappropriate broad-spectrum antibiotic use

Chronic pulmonary aspergillosis missed or delayed in diagnosis, allowing fungal infection to progress

Fungal asthma misdiagnosed as COPD and treated with antibiotics and steroids instead of antifungals

Pneumocystis pneumonia (PCP) in HIV-positive patients treated unnecessarily with antibiotics

According to researchers at Rutgers University summarizing the GAFFI report, “Poor diagnosis worldwide of fungal disease causes doctors to overprescribe antibiotics, increasing harmful resistance to antimicrobial drugs”.

The research team concluded that “inadequate attention is paid to fungal infection as the cause of antibacterial treatment failure”.

Of the estimated 200 million asthma sufferers worldwide, between 6 million and 15 million have fungal asthma — a condition that responds to antifungal therapy and not to antibiotics.

Most of those patients are receiving the wrong treatment.

Orbital fungal infections — those affecting tissue around the eye — are misdiagnosed in two out of three cases, according to a 2023 study in PubMed.

The most common incorrect initial diagnoses were bacterial cellulitis and bacterial sinusitis. Nearly 15% of those patients received systemic steroids, which can actively worsen fungal infections.

The consequences of these misdiagnoses are severe.

When a patient with a fungal infection is treated with antibiotics instead of antifungals, two things happen simultaneously:

1. The antibiotics fail to address the fungal infection, and they continue to disrupt the gut microbiome — further suppressing the immune defenses that might have otherwise slowed fungal growth.

2. The window of treatment narrows. The infection deepens.

The Science of Fungal Infection: What’s Really Growing Inside

When bacteria are cleared from the gut and airways, opportunistic fungi move in fast.

The most common culprit is Candida albicans, a yeast that lives harmlessly in small amounts in most human bodies. Under normal conditions, beneficial bacteria keep Candida in check. Under antibiotic pressure, it colonizes aggressively.

Candida can progress from surface colonization to invasive candidiasis — a condition where the yeast enters the bloodstream and spreads to organs including the kidneys, liver, heart, and brain.

This progression is called candidemia, and it is one of the deadliest hospital-acquired infections in the world.

According to a 2024 global incidence study published in The Lancet Infectious Diseases, approximately 1,565,000 people develop Candida bloodstream infections or invasive candidiasis each year, with approximately 995,000 deaths — a fatality rate of 63.6%.

Invasive aspergillosis, another major fungal infection often triggered by antibiotic disruption, kills more than 1.8 million people annually.

A 2021 study tracking 807 patients with candidemia found that cumulative all-cause mortality was 21.4% at 7 days, 36.4% at 30 days, and 43.2% at 90 days.

ICU patients fared even worse — their mortality rates were approximately twice as high as non-ICU patients at every time point.

Beyond Candida, Aspergillus fumigatus — the airborne mold spore most associated with indoor water damage and HVAC contamination — is a secondary opportunistic infection risk in antibiotic-disrupted patients.

A 2026 study published in PubMed found that antibiotic-induced microbiota disruption impairs neutrophil-mediated immunity to respiratory Aspergillus fumigatus infections in mice.

In practical terms: people who have recently taken antibiotics may be more susceptible to Aspergillus infections from mold in their homes or workplaces.

Candida auris: The Antibiotic-Fueled Superbug

No fungal story today is complete without addressing Candida auris — a newly emerging, multidrug-resistant fungal pathogen that the CDC has designated as an urgent antimicrobial resistance threat.

C. auris thrives in exactly the conditions created by heavy antibiotic use: depleted microbiomes, immunocompromised patients, long hospital stays, and broad-spectrum antibiotic treatment.

A 2021 study in Oxford Academic found that receiving carbapenem antibiotics was a significant independent risk factor for C. auris colonization.

The CDC explicitly identifies long-term overuse of antimicrobials as a primary risk factor for C. auris infection, noting that antibiotics and antifungals “should be used carefully and stopped when no longer needed”.

The numbers are alarming.

A 2025 study found that in C. auris invasive infection cases, prior use of three or more antibiotics was a significant risk factor, and the overall mortality rate in patients with invasive infection was 75%. A 2026 CDC analysis found that over 95% of C. auris isolates are now resistant to fluconazole, the first-line antifungal treatment.

According to CDC epidemiologist Dr. Meghan Lyman, “The rapid rise and geographic spread of cases is concerning and emphasizes the need for continued surveillance, expanded lab capacity, quicker diagnostic tests, and adherence to proven infection prevention and control”.

Why Diagnosis Is Failing Patients

One of the clearest explanations for why this crisis persists is the state of fungal diagnostics.

Diagnosing a fungal infection currently requires specialized laboratory tools, trained personnel, and in many cases, several days of waiting for culture results.

In the meantime, doctors treat empirically — and empirical treatment defaults to antibiotics.

According to research published in The Conversation, “Due to a lack of fast and accurate diagnostic tests, the prescription of antimicrobial drugs is rarely based on an accurate diagnosis.”

Hospital patients with serious fungal infections are often prescribed broad-spectrum antimicrobial drugs instead.

The GAFFI researchers concluded bluntly:

“The lack of availability and underuse of nonculture fungal diagnostics results in overprescribing, prescription of unduly long courses of antibacterial agents, and excess empirical use of antifungal agents and leaves many millions of patients with undiagnosed fungal infections”.

Tools that exist but are underused include:

  • 1,3 β-D-glucan testing — a blood marker for fungal infection
  • Bronchoscopy and bronchoalveolar lavage microscopy — useful for pulmonary fungal infections such as PCP
  • Galactomannan antigen detection — used to identify Aspergillus infections
  • Fungal cultures and skin testing — helpful for diagnosing fungal asthma

The underuse of these tools is not simply a technical failure. It reflects a system-wide blind spot: fungal infections are treated as rare, exotic, or secondary concerns, when in reality they are killing millions of people each year.

The Mold Connection: Environmental Exposure Meets a Compromised Immune System

For homeowners and tenants, the intersection of antibiotic use and indoor mold exposure is a real and underappreciated risk. Most people know that black mold — Stachybotrys chartarum — releases mycotoxins that can damage the respiratory system, nervous system, and immune function.

What fewer people understand is that antibiotic-disrupted patients are significantly more vulnerable to mold spore infections from their own living environment.

Aspergillus species, which grow on water-damaged walls, ceiling tiles, HVAC systems, and wood, are the primary cause of invasive aspergillosis. For a patient who has recently been on broad-spectrum antibiotics, whose gut microbiome is depleted and whose anti-fungal immune signaling is suppressed, inhaling Aspergillus spores at home poses a genuine infection risk.

Water-damaged buildings create the ideal conditions for mold growth: relative humidity above 60%, organic building materials, and warmth.

According to the U.S. Environmental Protection Agency, “Mold growth can begin within 24 to 48 hours after water exposure.” Once established, mold colonies release millions of spores into indoor air continuously.

For immunocompetent individuals, this is a respiratory irritant.

For post-antibiotic patients, it can be a life-threatening encounter.

Practical Steps: What You Can Do Right Now

Understanding this problem gives you the power to act. Here are concrete steps for patients, caregivers, and property managers.

For patients taking or recovering from antibiotics:

Ask your doctor whether a probiotic regimen during and after antibiotics is appropriate for you

Be aware that new or worsening symptoms during antibiotic treatment may indicate a fungal infection rather than treatment failure

If you are not improving within 5–7 days of antibiotic treatment, ask your doctor specifically about fungal infection testing

Avoid high-sugar diets during antibiotic courses — sugar feeds Candida proliferation

Discuss with your physician whether antifungal prophylaxis is warranted if you are immunocompromised, elderly, or scheduled for invasive surgery

For anyone concerned about indoor mold exposure:

Use a hygrometer to monitor indoor humidity; keep it below 50–55%

Inspect and clean HVAC systems regularly, as ductwork is a primary reservoir for Aspergillus spores

Fix water leaks immediately; mold can begin growing within 24–48 hours of moisture exposure

If water damage has occurred, hire a certified mold inspector before re-occupying the space

If you are immunocompromised, post-surgery, or recently on antibiotics, consider wearing an N95 mask during any remediation activity

For healthcare providers and patients in clinical settings:

Push for expanded use of nonculture fungal diagnostics, especially 1,3 β-D-glucan testing, in patients not responding to antibiotics

Antibiotic stewardship — using the narrowest spectrum antibiotic for the shortest effective duration — is one of the most effective tools for preventing antibiotic-induced fungal disease

Screen high-risk patients (ICU residents, the immunocompromised, the elderly, those on mechanical ventilation) for fungal colonization, especially C. auris

Conclusion

The story of antibiotics and fungal infections is a story about unintended consequences at massive scale.

Antibiotics save lives — but they also disrupt the microbial ecosystems that protect us from fungi, suppress the immune responses that contain fungal growth, and create the exact conditions under which opportunistic pathogens like Candida and Aspergillus thrive.

When fungal infections are then misdiagnosed as bacterial ones — which happens in the majority of clinical scenarios where they overlap — patients receive more of the same medicine that made them vulnerable in the first place.

The infection worsens.

Time is lost.

And for hundreds of thousands of people each year, the outcome is fatal.

Awareness is the first line of defense.

If you are a patient who is not getting better on antibiotics, ask about fungal testing.

If you live or work in a building with water damage, take mold exposure seriously — especially after a course of antibiotics.

And if you are a clinician, consider whether the next prescription for failing antibiotic treatment should include a fungal workup.

The fungi are waiting.

The best defense is knowing they are there.

References

Authors

  • Moe Bedard

    Moe is a certified mold inspector and remediator with 15+ years of experience, founder of Black Mold News, and CEO of Mold Safe Solutions—making him one of the most trusted names in the industry.

  • Chase Bedard is the Lead Science Researcher and Editor for Black Mold News and a graduate of the University of California, San Diego in cell biology. He is also a certified mold inspector and remediator with Mold Safe Solutions, combining scientific training with real-world field experience investigating mold and its health effects in homes and buildings.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *